Online inquiry

IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11613MR)

This product GTTS-WQ11613MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&IL3RA gene. The antibody can be applied in Acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Mus musculus; Humanized
RefSeq NM_000733.4; NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 3563
UniProt ID P07766; P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11613MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15858MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XmAb5871
GTTS-WQ14634MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ15392MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ10698MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ3154MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ11742MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MK-0646
GTTS-WQ5087MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ12510MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NOE-102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW